Myeloproliferative Disorders

We provide expert care in diagnosing and treating people with myeloproliferative disorders—rare conditions in which the bone marrow does not function properly and makes too many blood cells. Our specialists use advanced testing to identify these chronic, often lifelong conditions that can be difficult to diagnose. Based on your individual needs, we create a comprehensive, long-term treatment plan that includes support services, such as rehabilitation, counseling, and integrative health therapies.

Clinical Trials and Research Studies

Phase 2

Single-arm open label phase II study of MBG453 (sabatolimab) added to FDA approved Hypomethylating agents of investigator s choice (IV/SC/Oral) for patients with intermediate high or very high risk myelodysplastic syndrome (MDS) as per IPSS-R criteria (US multi-center) (STIMULUS MDS-US)

Learn More

Phase 3

A Phase 3 Randomized Multicenter Double-Blind Placebo-Controlled Efficacy and Safety Study of Birtamimab Plus Standard of Care vs. Placebo Plus Standard of Care in Mayo Stage IV Subjects with Light Chain (AL) Amyloidosis

Learn More

Phase 1

A First in Human Study of theMenin-KMT2A (MLL1)Inhibitor JNJ-75276617 in Participants with Acute Leukemia

Learn More

Phase 1

A Phase 1 Open-label Preliminary Pharmacokinetics (PK) and Safety Study of CLN-049 (An fms-like tyrosine kinase 3 [FLT3] x cluster of differentiation 3 [CD3] bispecific T cell engager) in Patients with Relapsed/Refractory Acute Myeloid Leukemia (AML)

Learn More